Our mission is to deploy our platform technology across a pipeline of drugs, targeting largely unmet medical conditions in which RAS is implicated.
We and our collaborators are global leaders in the chemistry and biology of RAS deactivation and how this strategy can treat CNS related disorders including trauma and neurodegenerative diseases. Our first indication will be neuropathic pain in spinal cord injury (SCI), a condition which affects 50% of SCI patients, for whom current treatments, including addictive opioids, are significantly inadequate.
As we progress through clinical trials in SCI neuropathic pain, we will extend our indications to address other sources of neuropathic pain (e.g., chemotherapy, diabetes) and neuro-degenerative disease, such as multiple sclerosis and Parkinsons, in which RAS contributes to progression, pain and lack of mobility.
Our team is devoted to pursue Neuro Vigor's objective of neutralizing RAS.
Translational Neuroscientist with broad expertise in drug discovery/development for neurological indications. Listed inventor on >10 small and large molecule patents including NVG-291 composition of matter (P1 clinical trials). Scientific Founder of Nervgen, VP of Research of Convelo Therapeutics.